The tyrosine-kinase inhibitor cabozatinib does not increase overall survival compared with prednisone. However, significant increases in progression-free survival duration have been observed with this approach. Now, investigations involving PTEN/P53-deficient mouse models reveal remarkable responses to cabozantinib that are mediated by robust neutrophil-mediated infiltration of the tumour. These results indicate a novel mechanism of action of cabozantinib.
References
Patnaik, A. et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-16-0778 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Cabozantinib activates innate immunity. Nat Rev Urol 14, 327 (2017). https://doi.org/10.1038/nrurol.2017.50
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.50
This article is cited by
-
Current perspectives on bone metastases in castrate-resistant prostate cancer
Cancer and Metastasis Reviews (2018)